Supplemental Table 1: Means and Standard Deviations of All Outcome Measures by Time Point

Patient-reported Outcome	Time Point*	Number of Observations	Mean	Standard Deviation
QOL: FACT-G	Baseline	98	76.1	17.1
QOL: FACT-G	1 Week	95	71.1	16.9
QOL: FACT-G	1 Month	85	76.8	15.8
QOL: FACT-G	3 Months	80	81.3	16.4
QOL: FACT-G	6 Months	72	81.5	16.2
Anxiety: HADS-A	Baseline	100	5.58	4.17
Anxiety: HADS-A	1 Week	95	4.73	4.28
Anxiety: HADS-A	1 Month	86	4.93	3.91
Anxiety: HADS-A	3 Months	80	4.84	3.90
Anxiety: HADS-A	6 Months	72	4.20	3.62
Depression: HADS-D	Baseline	100	5.47	4.07
Depression: HADS-D	1 Week	95	6.17	4.97
Depression: HADS-D	1 Month	86	5.83	4.58
Depression: HADS-D	3 Months	80	4.72	3.55
Depression: HADS-D	6 Months	72	4.43	3.86
Depression: PHQ-9	Baseline	99	5.74	5.29
Depression: PHQ-9	1 Week	95	6.76	5.55
Depression: PHQ-9	1 Month	84	5.36	4.11
Depression: PHQ-9	3 Months	80	4.15	3.82
Depression: PHQ-9	6 Months	72	4.23	4.27
PTSD Symptoms: PCL	Baseline	98	29.0	9.39
PTSD Symptoms: PCL	1 Month	86	26.7	8.55
PTSD Symptoms: PCL	3 Months	80	27.5	9.00
PTSD Symptoms: PCL	6 Months	72	27.2	9.77

Quality of life: QOL; PTSD: Post-traumatic stress disorder

*1 week, 1 month, 3 months, and 6 months time points refer to time post CAR-T infusion.

Supplemental Figure 1: Consort Diagram

Eligible 149	→	**Not approached: 8** MD raised objection: 3 COVID-19: 2 Too ill to approach: 1 Competing clinical trial: 1 Logistically unable to approach patient: 1

Approached but did not participate: 38
Too overwhelmed: 11
Did not complete baseline: 11
Not interested in research: 6
Not interested or concerned about surveys: 4
Language barrier not documented in chart: 2
Unable to complete approach due to COVID-19: 2
Concerned about privacy: 1
No reason given: 1

Approached 141

Enrolled 103

Excluded 3 Did not proceed to CAR-T cell therapy

Received CAR-T cell Therapy 100